Rezo Therapeutics

Drug discovery is hindered by limited ability to precisely identify and target disease-relevant protein–protein interactions and their interfaces.

The company maps protein–protein interaction networks and interfaces at high resolution to enable development of precision small-molecule therapeutics.

Pharmaceutical and biotechnology companies developing small-molecule therapeutics use this technology.